Court of Appeals for the D.C. Circuit June 3, 2005, 05-5004 (Teva Pharmaceutical Industries Ltd. v. Crawford)
Also known as
United States · · · 03-06-2005
United States Court of Appeals
FOR THE DISTRICT OF COLUMBIA CIRCUIT
Argued May 9, 2005 Decided June 3, 2005
No. 05-5004
TEVA PHARMACEUTICAL INDUSTRIES LTD . AND
TEVA PHARMACEUTICALS, USA, INC.,
APPELLANTS
v.
LESTER M. CRAWFORD, JR., ACTING COMMISSIONER OF FOOD
AND DRUGS, ET AL.,
APPELLEES
Appeal from the United States District Court
for the District of Columbia
(No. 04cv01416)
William H. Rooney argued the cause for appellants.
With him on the briefs were Theodore C. Whitehouse and James
N. Czaban.
William A. Rakoczy, Christine J. Siwik, Amy D. Brody,
and Lara E. Monroe-Sampson were on the brief for amicus
curiae Mylan Pharmaceuticals, Inc. in support of appellants.
Jeffrey S. Bucholtz, Deputy Assistant Attorney General,
U.S. Department of Justice, argued the cause for federal
appellees. With him on the brief were Peter D. Keisler,
2
Assistant Attorney General, Eugene M. Thirolf, Director,
Andrew E. Clark, Attorney, Alex M. Azar, II, General Counsel,
Food & Drug Administration, and Eric M. Blumberg, Deputy
Chief Counsel.
Bert W. Rein argued the cause for appellees Pfizer Inc.,
et al. With him on the brief were Karyn K. Ablin and Jeffrey B.
Chasnow.
Before: GINSBURG , Chief Judge, and SENTELLE and
ROGERS, Circuit Judges.
Opinion for the Court filed by Chief Judge GINSBURG.
GINSBURG, Chief Judge: Teva Pharmaceutical Industries
has sued to overturn the Food and Drug Administration’s denial
of its “citizen petition” requesting that the agency prohibit
Pfizer, Inc., the holder of the approved New Drug Application
(NDA) for gabapentin, from marketing that drug in “generic”
form during the 180-day exclusivity period provided by the
Drug Price Competition and Patent Term Restoration Act, also
known as the “Hatch-Waxman Amendments” to the Food, Drug,
& Cosmetic Act. Because the exclusivity provision does not
apply to the holder of an approved NDA, the district court
entered a summary judgment for the FDA, which we now
affirm.
I. Background
Section 355(j) of 21 U.S.C.
Read the full text
This document is published by courtlistener.com.
Moonlit adds the citation network, article-level links and cross-references, which are available to search for free.
Sign in to Moonlit